Pinnacle Associates Ltd. Acquires 39,271 Shares of Progyny, Inc. $PGNY

Key Points

• Pinnacle Associates acquired 39,271 Progyny shares during the third quarter, worth approximately $989,000. Institutional investors collectively own 94.93% of the company.
• Progyny reported quarterly EPS of $0.55, exceeding the $0.33 analyst consensus, while revenue rose 5.3% year over year to $350.51 million. The company issued third-quarter 2026 EPS guidance of $0.50–$0.52.
• Analyst sentiment remains positive overall, with a consensus “Moderate Buy” rating and an average price target of $34.36 versus the stock’s reported $28.97 price; however, insiders sold 17,282 shares worth about $475,790 over the past three months.

Pinnacle Associates Ltd. acquired a new position in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 39,271 shares of the company's stock, valued at approximately $989,000. Pinnacle Associates Ltd. owned about 0.05% of Progyny as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Toth Financial Advisory Corp grew its stake in Progyny by 21.3% during the 3rd quarter. Toth Financial Advisory Corp now owns 2,735 shares of the company's stock worth $69,000 after buying an additional 480 shares during the last quarter. Public Employees Retirement System of Ohio acquired a new position in Progyny during the second quarter worth approximately $29,000. Nykredit A S acquired a new position in Progyny during the second quarter worth approximately $38,000. Allworth Financial LP increased its position in Progyny by 71.7% during the second quarter. Allworth Financial LP now owns 3,259 shares of the company's stock worth $94,000 after buying an additional 1,361 shares during the period. Finally, Versant Capital Management Inc lifted its stake in Progyny by 53.3% in the second quarter. Versant Capital Management Inc now owns 4,330 shares of the company's stock valued at $125,000 after buying an additional 1,506 shares during the last quarter. Institutional investors and hedge funds own 94.93% of the company's stock.

Insider Activity at Progyny

In related news, COO Melissa Cummings sold 1,879 shares of Progyny stock in a transaction on Wednesday, October 14th. The shares were sold at an average price of $28.00, for a total value of $52,612.00. Following the transaction, the chief operating officer directly owned 66,496 shares in the company, valued at $1,861,888. This trade represents a 2.75% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kevin Gordon sold 11,500 shares of the business's stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $27.94, for a total transaction of $321,310.00. Following the completion of the transaction, the director directly owned 6,792 shares in the company, valued at $189,768.48. This represents a 62.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 17,282 shares of company stock worth $475,790 in the last three months. Insiders own 9.90% of the company's stock.

Progyny Trading Down 0.5%

Shares of PGNY stock opened at $28.97 on Friday. The business's 50 day moving average is $26.62 and its two-hundred day moving average is $25.87. Progyny, Inc. has a twelve month low of $16.10 and a twelve month high of $33.06. The company has a market capitalization of $2.22 billion, a P/E ratio of 31.49, a price-to-earnings-growth ratio of 2.00 and a beta of 1.02.

Progyny (NASDAQ:PGNY - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported $0.55 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.33 by $0.22. Progyny had a return on equity of 15.98% and a net margin of 6.00%. The business had revenue of $350.51 million for the quarter, compared to analyst estimates of $349.05 million. During the same quarter in the previous year, the company posted $0.19 earnings per share. The company's revenue for the quarter was up 5.3% compared to the same quarter last year. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. As a group, equities analysts predict that Progyny, Inc. will post 1.25 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on PGNY. Zacks Research downgraded Progyny from a "strong-buy" rating to a "hold" rating in a report on Monday, October 19th. Wall Street Zen upgraded shares of Progyny from a "buy" rating to a "strong-buy" rating in a research report on Saturday, September 19th. Wells Fargo & Company initiated coverage on shares of Progyny in a report on Wednesday, September 30th. They issued an "overweight" rating and a $37.00 target price on the stock. Truist Financial lifted their target price on shares of Progyny from $33.00 to $36.00 and gave the company a "buy" rating in a report on Thursday, August 13th. Finally, Barclays reduced their price target on shares of Progyny from $34.00 to $30.00 and set an "equal weight" rating for the company in a research report on Wednesday, August 12th. Nine research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, Progyny has a consensus rating of "Moderate Buy" and an average target price of $34.36.

Progyny Company Profile

Progyny, Inc is a benefits-management company focused on fertility and family-building care. The company works with employers to provide comprehensive benefits that help members access fertility treatments and related services through a network of specialized providers.

Its offerings include coverage and support for services such as in vitro fertilization, fertility testing, egg and sperm freezing, donor services, gestational surrogacy, and adoption. Progyny also provides pharmacy benefits through Progyny Rx, as well as personalized guidance intended to help members navigate treatment options, providers, and the broader family-building process.

Progyny primarily serves self-insured employers and their employees in the United States.

Want to see what other hedge funds are holding PGNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progyny, Inc. (NASDAQ:PGNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.